Literature DB >> 30614815

Rationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies.

Mark W Dewhirst1, Yvonne M Mowery1, James B Mitchell2, Murali K Cherukuri2, Timothy W Secomb3.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30614815      PMCID： PMC6355230          DOI： 10.1172/JCI126044

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  19 in total

1.  Theoretical simulation of oxygen transport to tumors by three-dimensional networks of microvessels.

Authors:  T W Secomb; R Hsu; R D Braun; J R Ross; J F Gross; M W Dewhirst
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

Review 2.  Molecular aspects of cancer cell resistance to chemotherapy.

Authors:  Magali Rebucci; Carine Michiels
Journal:  Biochem Pharmacol       Date:  2013-02-19       Impact factor: 5.858

3.  A potential solution for eliminating hypoxia as a cause for radioresistance.

Authors:  Mark W Dewhirst
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-09       Impact factor: 11.205

Review 4.  Transport of drugs from blood vessels to tumour tissue.

Authors:  Mark W Dewhirst; Timothy W Secomb
Journal:  Nat Rev Cancer       Date:  2017-11-10       Impact factor: 60.716

Review 5.  Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.

Authors:  Dearbhaile C Collins; Raghav Sundar; Joline S J Lim; Timothy A Yap
Journal:  Trends Pharmacol Sci       Date:  2016-11-18       Impact factor: 14.819

6.  Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers.

Authors: 
Journal:  Semin Radiat Oncol       Date:  1996-01       Impact factor: 5.934

Review 7.  Immune targets and neoantigens for cancer immunotherapy and precision medicine.

Authors:  Rong-Fu Wang; Helen Y Wang
Journal:  Cell Res       Date:  2016-12-27       Impact factor: 25.617

8.  Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.

Authors:  Yuhui Huang; Jianping Yuan; Elda Righi; Walid S Kamoun; Marek Ancukiewicz; Jean Nezivar; Michael Santosuosso; John D Martin; Margaret R Martin; Fabrizio Vianello; Pierre Leblanc; Lance L Munn; Peigen Huang; Dan G Duda; Dai Fukumura; Rakesh K Jain; Mark C Poznansky
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

9.  Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.

Authors:  Priyamvada Jayaprakash; Midan Ai; Arthur Liu; Pratha Budhani; Todd Bartkowiak; Jie Sheng; Casey Ager; Courtney Nicholas; Ashvin R Jaiswal; Yanqiu Sun; Krishna Shah; Sadhana Balasubramanyam; Nan Li; Guocan Wang; Jing Ning; Anna Zal; Tomasz Zal; Michael A Curran
Journal:  J Clin Invest       Date:  2018-10-15       Impact factor: 14.808

10.  CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells.

Authors:  Timo Gaber; Kerstin Schönbeck; Holger Hoff; Cam Loan Tran; Cindy Strehl; Annemarie Lang; Sarah Ohrndorf; Moritz Pfeiffenberger; Eric Röhner; Georg Matziolis; Gerd-R Burmester; Frank Buttgereit; Paula Hoff
Journal:  Int J Mol Sci       Date:  2018-08-07       Impact factor: 5.923
View more
  10 in total

1.  Relief of tumor hypoxia unleashes the tumoricidal potential of neutrophils.

Authors:  Karim Mahiddine; Adam Blaisdell; Stephany Ma; Amandine Créquer-Grandhomme; Clifford A Lowell; Adrian Erlebacher
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

2.  Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.

Authors:  Shun Kishimoto; Jeffrey R Brender; Gadisetti V R Chandramouli; Yu Saida; Kazutoshi Yamamoto; James B Mitchell; Murali C Krishna
Journal:  Antioxid Redox Signal       Date:  2020-09-15       Impact factor: 7.468

Review 3.  Effects of impaired microvascular flow regulation on metabolism-perfusion matching and organ function.

Authors:  Tuhin K Roy; Timothy W Secomb
Journal:  Microcirculation       Date:  2020-12-21       Impact factor: 2.679

Review 4.  Trends and Challenges in Tumor Anti-Angiogenic Therapies.

Authors:  József Jászai; Mirko H H Schmidt
Journal:  Cells       Date:  2019-09-18       Impact factor: 6.600

Review 5.  Implementation of the Chick Chorioallantoic Membrane (CAM) Model in Radiation Biology and Experimental Radiation Oncology Research.

Authors:  Nicole Dünker; Verena Jendrossek
Journal:  Cancers (Basel)       Date:  2019-10-07       Impact factor: 6.639

6.  Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients.

Authors:  Run Shi; Xuanwen Bao; Kristian Unger; Jing Sun; Shun Lu; Farkhad Manapov; Xuanbin Wang; Claus Belka; Minglun Li
Journal:  Theranostics       Date:  2021-03-05       Impact factor: 11.556

7.  Genomic Profiling of Chinese Cervical Cancer Patients Reveals Prevalence of DNA Damage Repair Gene Alterations and Related Hypoxia Feature.

Authors:  Hao Wen; Qin-Hao Guo; Xiao-Lan Zhou; Xiao-Hua Wu; Jin Li
Journal:  Front Oncol       Date:  2022-01-07       Impact factor: 6.244

Review 8.  Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment.

Authors:  Rosamaria Lappano; Lauren A Todd; Mia Stanic; Qi Cai; Marcello Maggiolini; Francesco Marincola; Violena Pietrobon
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

9.  Macrophage-targeted anti-CCL2 immunotherapy enhances tumor sensitivity to 5-fluorouracil in a Balb/c-CT26 murine colon carcinoma model measured using diffuse reflectance spectroscopy.

Authors:  Shelby N Bess; Gage J Greening; Narasimhan Rajaram; Timothy J Muldoon
Journal:  BMC Immunol       Date:  2022-04-23       Impact factor: 3.594

Review 10.  Hypoxia and its therapeutic possibilities in paediatric cancers.

Authors:  Carolina Bernauer; Y K Stella Man; Julia C Chisholm; Elise Y Lepicard; Simon P Robinson; Janet M Shipley
Journal:  Br J Cancer       Date:  2020-10-27       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.